Beam Therapeutics Inc. (BEAM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $1.11 per share a year ago.
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains?
Beam Therapeutics (BEAM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases
Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from phase 1/2 BEACON study using BEAM-101, expected in the 2nd half of 2025. The global sickle cell disease market is expected to reach $12.38 billion by 2032.
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago.
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy
Recently, BEAM reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. Unfortunately, they concurrently announced a $500 million equity offering, which may have caused concerns about near-term dilution. Still, BEAM-302 has innovative in vivo base editing technology that could potentially offer a one-time curative therapy for patients suffering from AATD.
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.
